TScan Therapeutics, Inc. (TCRX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
TScan Therapeutics, Inc. (TCRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Garry Nicholson and Gabriela Gruia, M.D. On October 13, 2026, each of Garry Nicholson and Gabriela Gruia, M.
How this was made
The 30-second read
Why it matters
The filing provides the first public notice of the board changes, offering a brief window for traders to adjust positions before any market reaction.
Market read
Governance update with limited price impact; relevant for short‑term traders monitoring micro‑cap biotech stocks.
What to watch
Potential upcoming clinical trial milestones that could dominate investor focus.
Background
TScan Therapeutics filed an 8‑K announcing director resignations and new appointments, a routine corporate governance disclosure.
Ticker impact
SEC Form 8‑K reports resignation of two directors and appointment of new board members at TScan Therapeutics.
likely modest pressure as investors assess governance changes
Director resignations are disclosed for the first time; market typically reacts modestly to such governance updates.
Market effects
Minimal effect on biotech sector; governance changes are company‑specific.
No broader regional impact.
Limited to investors tracking micro‑cap biotech stocks.
Counterpoint
Board changes could signal internal disagreements that may affect future financing.
Key entities
- companyTScan Therapeutics, Inc.
Biotech firm listed on Nasdaq under ticker TCRX.
- personGarry Nicholson
Resigning director.
- personGabriela Gruia, M.D.
Resigning director.
